New drug cocktail aims to tame tough pancreatic cancer

NCT ID NCT05273554

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This early study tests whether combining two drugs, pembrolizumab (Keytruda) and lenvatinib, can help control advanced pancreatic cancer that has already been treated. Fifteen participants will receive the combination to see if it shrinks tumors. The goal is to gather initial data on effectiveness and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab (Keytruda) and lenvatinib
What this could lead to: If it works, this could point toward a new treatment option for advanced pancreatic cancer that has not responded to prior therapy.
What could go wrong: This is a very early, small pilot study with only 15 participants. The combination may not shrink tumors or improve survival, and side effects from the drugs could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma neoplasm pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOCARCINOMA TUMOR

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.